In a study conducted by our institution focusing on the use of bevacizumab in recurrent GBM, we employed the Polymerase Chain Reaction (PCR) - Restriction Fragment Length Polymorphism (RFLP) technique to investigate the CDKN1A (p21) c.93 C > A gene polymorphism [8]. Here, CDKN1A is linked to glioblastoma.